Drugs / Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin
Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00074230 | Jul 2003 → Mar 2014 | cutaneous melanoma | University Hospital Erlangen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00074230 ↗ |
| Modality | Cell therapy | “autologous monocyte-derived dendritic cells (DC) transfected with RNAs encoding Melan-A, MAGE-3, and survivin antigens” NCT00074230 ↗ |
| Route | Other | “patients received the vaccine intradermally” NCT00074230 ↗ |